Applied Genetic Technologies Corporation (NASDAQ:AGTC) shares hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $4.47 and last traded at $4.60, with a volume of 189,019 shares trading hands. The stock had previously closed at $4.70.

A number of research analysts have issued reports on AGTC shares. Stifel Nicolaus cut their price target on shares of Applied Genetic Technologies Corporation from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, May 11th. Zacks Investment Research lowered shares of Applied Genetic Technologies Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. ValuEngine lowered shares of Applied Genetic Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Cantor Fitzgerald set a $15.00 price target on shares of Applied Genetic Technologies Corporation and gave the company a “hold” rating in a research note on Wednesday, May 10th. Finally, HC Wainwright set a $16.00 price target on shares of Applied Genetic Technologies Corporation and gave the company a “buy” rating in a research note on Thursday, August 10th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $13.81.

The firm has a 50 day moving average price of $4.81 and a 200-day moving average price of $5.80. The firm has a market cap of $81.34 million, a PE ratio of 10.74 and a beta of 1.68.

Institutional investors have recently made changes to their positions in the company. Prudential Financial Inc. increased its holdings in shares of Applied Genetic Technologies Corporation by 24.2% in the 1st quarter. Prudential Financial Inc. now owns 155,210 shares of the biotechnology company’s stock valued at $1,071,000 after acquiring an additional 30,200 shares during the period. Algert Global LLC increased its holdings in shares of Applied Genetic Technologies Corporation by 9.8% in the 1st quarter. Algert Global LLC now owns 73,335 shares of the biotechnology company’s stock valued at $506,000 after acquiring an additional 6,540 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Applied Genetic Technologies Corporation by 1.1% in the 1st quarter. Wells Fargo & Company MN now owns 19,005 shares of the biotechnology company’s stock valued at $131,000 after acquiring an additional 200 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of Applied Genetic Technologies Corporation by 2.5% in the 1st quarter. Russell Investments Group Ltd. now owns 77,710 shares of the biotechnology company’s stock valued at $535,000 after acquiring an additional 1,883 shares during the period. Finally, Bank of Montreal Can increased its holdings in shares of Applied Genetic Technologies Corporation by 44.5% in the 1st quarter. Bank of Montreal Can now owns 56,732 shares of the biotechnology company’s stock valued at $392,000 after acquiring an additional 17,481 shares during the period. 54.75% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/05/applied-genetic-technologies-corporation-agtc-reaches-new-52-week-low-at-4-47.html.

Applied Genetic Technologies Corporation Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).